I was talking to some folks at a big global pharma last week and I discovered that pharma doesn’t like social networking. (Give me a break – I’m a software security guy, I think about these things in terms of threats to intellectual property and I thought everyone “gets” social networking). If you understand how pharmaceuticals are sold, this is not surprising but it seemed worthwhile to take some time and learn more about the great pharma-social networking divide before diving into a more detailed discussion of why pharmas have a problem with social media (mostly regulation but not just).
Poland is leading the way in Europe with a new law enacted as of December 1, 2008 that prohibits medical representatives from visiting doctors during business hours. Reps are a good source of spoon-fed science for docs, not to mention the free samples and perks at conferences. However – over 90,000 doctors in Poland have quickly adjusted to a new reality and the big pharmas like GSK, Roche, Schering-Plough / Merck have accepted that times are a changing.
Current sales indicators of how many face to face visits a rep made are not going to cut it anymore. The question is – what next?
Counterfeiting is old as money itself.
We recently had the opportunity to work with a large generic pharmaceutical company examining innovative methods for preventing product counterfeiting. In order to build cost justification for the project, we performed a quantitative threat modeling exercise that involved valuation of assets and analysis of a number of product counterfeiting threat scenarios.
The threat model is available on request – please contact us and we will be happy to send you a copy of the threat model and an explanation of how to use it in your own product counterfeiting scenarios.
The first question to be asked – what is the volume of financial damage due to drug counterfeiting?